Slowing lung damage in IPF: Can Losartan and Pirfenidone Work Better Together?

Effect of Combination Therapy with Pirfenidone and Losaratn on Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250508065656N1

Enrollment

Registered

2025-05-20

Start date

2025-05-22

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis. Other interstitial pulmonary diseases with fibrosis

Interventions

Intervention 1: Intervention group: Receiving pirfenidone (600 mg daily) and losartan (50 mg daily) for 6 months. Intervention 2: Control group: Receiving pirfenidone (600 mg daily) and placebo for 6

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Established IPF with radiologic signs Systolic Blood Pressure larger than 110

Exclusion criteria

Exclusion criteria: Obstructive Airway Disease Connective Tissue Disease Alternative explanation for Interstitial Lung Disease Greater extent of emphysema then of fibrosis History of taking Losartan

Design outcomes

Primary

Measure	Time frame
Forced Vital Capacity (FVC): The volume of air that can forcibly be blown out after full inspiration. Timepoint: Before intervention, 6 months after intervention. Method of measurement: Spirometry.	—

Secondary

Measure	Time frame
Forced expiratory volume in 1 second (FEV1): volume of air that can forcibly be blown out in first 1-second, after full inspiration. Timepoint: Before intervention and 6 months after. Method of measurement: Spirometry.;Total lung capacity (TLC): the maximum volume of air present in the lungs. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Spirometry.;Diffusing capacity (DLCO): the carbon monoxide uptake from a single inspiration in a standard time. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Spirometry.;Distance covered by the patient in the 6-minute walk test. Timepoint: Before intervention and 6 months after intervention. Method of measurement: 6-minute walk test.;Blood oxygen saturation levels in the 6-minute walk test. Timepoint: Before intervention and 6 months after intervention. Method of measurement: 6-minute walk test.;Severity of shortness of breath based on the Borg scale in the 6-minute walk test. Timepoint: Before intervention and 6 months after intervention. Method of measurement: 6-minute walk test.	—

Measure

Time frame

Forced expiratory volume in 1 second (FEV1): volume of air that can forcibly be blown out in first 1-second, after full inspiration. Timepoint: Before intervention and 6 months after. Method of measurement: Spirometry.;Total lung capacity (TLC): the maximum volume of air present in the lungs. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Spirometry.;Diffusing capacity (DLCO): the carbon monoxide uptake from a single inspiration in a standard time. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Spirometry.;Distance covered by the patient in the 6-minute walk test. Timepoint: Before intervention and 6 months after intervention. Method of measurement: 6-minute walk test.;Blood oxygen saturation levels in the 6-minute walk test. Timepoint: Before intervention and 6 months after intervention. Method of measurement: 6-minute walk test.;Severity of shortness of breath based on the Borg scale in the 6-minute walk test. Timepoint: Before intervention and 6 months after intervention. Method of measurement: 6-minute walk test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Samet

Yazd University of Medical Sciences

samet_mo@yahoo.com+98 35 3183 3434

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026